ライフサイエンスコーパス: discontinuation

1 grade 3 neutropenia, both requiring therapy discontinuation).

2 of which were serious; two led to treatment discontinuation).

3 ment, and at 3 years (1 year after treatment discontinuation).

4 , including 92 before mechanical ventilation discontinuation.

5 id inhibition and decreased after medication discontinuation.

6 end </= .0001) and decreased with time since discontinuation.

7 more than one patient in any group or led to discontinuation.

8 toring, adverse events (AEs), and reason for discontinuation.

9 ss than 80% for any statin intensity without discontinuation.

10 iver cancer and died 22 days after treatment discontinuation.

11 n outcomes were all-cause mortality and drug discontinuation.

12 l or mental health precipitated by clozapine discontinuation.

13 disease progression or any other reason for discontinuation.

14 drawn individuals were not followed up after discontinuation.

15 says remained inhibited in part 1 year after discontinuation.

16 uction occurred in 25% without any treatment discontinuation.

17 No adverse events led to discontinuation.

18 uperior to haloperidol in terms of all-cause discontinuation.

19 ly testing, ART initiation, and limiting ART discontinuation.

20 mortality, ART non-initiation, or early ART discontinuation.

21 was insufficient for inhibition 1 year after discontinuation.

22 iratory, and in some patients it led to drug discontinuation.

23 ts had an adverse event leading to treatment discontinuation.

24 clinical benefit for several years after its discontinuation.

25 ce of rebounds or disease activity after its discontinuation.

26 emia or disease within 6 months of treatment discontinuation.

27 e events related to ridinilazole that led to discontinuation.

28 parately or in combination) after study drug discontinuation.

29 iratory adverse events, none of which led to discontinuation.

30 35.7% had treatment-related AEs that led to discontinuation.

31 in fill, was identified in the 365 days post-discontinuation.

32 d every 12 weeks thereafter until study drug discontinuation.

33 icity, or other protocol-defined reasons for discontinuation.

34 be suitable candidates for early antibiotic discontinuation.

35 barriers tend to result in longer-term care discontinuation.

36 tions, and factors associated with treatment discontinuation.

37 o evidence of opioid withdrawal on treatment discontinuation.

38 and cause relapse in most patients upon drug discontinuation.

39 hout significantly increasing the chances of discontinuation.

40 or drug-related adverse reactions requiring discontinuation.

41 oses of LMTM, and the most common causes for discontinuation.

42 thermore, these effects persisted after drug discontinuation.

43 atients had BCR-ABL1 mutations identified at discontinuation.

44 frequent cause of adverse events leading to discontinuation.

45 odies, and factors contributing to treatment discontinuation.

46 immunotherapy and for 1 year after treatment discontinuation.

47 in preventing disease reactivation after NTZ discontinuation.

48 ans identify candidates for early antibiotic discontinuation.

49 disease behaviour during treatment and after discontinuation.

50 were associated with shorter survival after discontinuation.

51 igen (PSA) rise after enzalutamide treatment discontinuation.

52 lso were significantly associated with early discontinuation.

53 ious adverse events or adverse event-related discontinuations.

54 ce that was not explained by early treatment discontinuations.

55 There were no premature treatment discontinuations.

56 d, most relapses occurred within 3 months of discontinuation (20 vs 7 relapses, p=0.012).

57 ere dose interruptions (46.4% vs. 13.2%) and discontinuations (28.1% vs. 5.6%).

58 o), and adverse events leading to study drug discontinuation (3% [49 patients] for both lebrikizumab

59 al improvement (2/12); clinical worsening on discontinuation (3/8)].

60 %]), and adverse events leading to treatment discontinuation (31 [14%] vs 15 [14%]) than did taxane t

61 nd fewer adverse events leading to treatment discontinuation (34 [7%] vs 78 [18%] patients).

62 VISUAL-1 was statistically higher than after discontinuation (454.2 per 100 patient-years [PY] vs. 36

63 ion had significantly shorter survival after discontinuation (6 vs 16 months).

64 ints included adverse events leading to drug discontinuation; adverse muscle, hepatobiliary, and neur

65 and patient disposition after pembrolizumab discontinuation after CR.

66 Opioid discontinuation after overdose is associated with lower

67 emain: (i) adverse events leading to therapy discontinuation and (ii) lack of reliable biomarkers.

68 this patient population, as evidenced by low discontinuation and adverse event rates, and were associ

69 The risk increased shortly after discontinuation and did not appear to diminish over time

70 Rates of discontinuation and dose reductions due to AEs were 17%

71 e hazard associated with late thienopyridine discontinuation and risk factors for MI after discontinu

72 estigated whether long-term low-dose aspirin discontinuation and treatment gaps increase the risk of

73 of which was serious; none led to treatment discontinuation) and 68 (26%) of 266 participants in the

74 alyze TB incidence, treatment completion and discontinuation, and cost-effectiveness.

75 e event of pneumonia, which led to treatment discontinuation, and during retreatment, 1 patient disco

76 on with subsequent all-cause death, dialysis discontinuation, and hospitalization controlled for demo

77 iated with increased risk of death, dialysis discontinuation, and hospitalization in dialysis patient

78 scriptions had increased mortality, dialysis discontinuation, and hospitalization.

79 ding adverse events, serious adverse events, discontinuations, and deaths; exploratory assessments in

80 iscontinuation and risk factors for MI after discontinuation are poorly defined.

81 IL-10 levels measured soon after prophylaxis discontinuation are predictive of CMV-dz risk.

82 were 34 cases of malaria, with 33 in the CTX discontinuation arm (IRR = 33.02, 95% CI 4.52-241.02; p

83 pecific quality of life (QOL) with treatment discontinuation at 1 year.

84 harm) with continued thienopyridine therapy, discontinuation at 12 months increases MI hazard regardl

85 ciated with an increased rate of second drug discontinuation because of adverse events (hazard ratio

86 erapies and decreased over time; second-line discontinuation because of adverse events was more commo

87 ive incidence of dose reduction or treatment discontinuation because of toxicity was nearly 40%.

88 No deaths, serious adverse events, or discontinuations because of adverse events were reported

89 o drug-related serious adverse events (AEs), discontinuations because of drug-related AEs, dose-limit

90 e increased anxiety, which can lead to early discontinuation before therapeutic effects are manifest.

91 2, 24, and 36 months, respectively, after NA discontinuation, being relatively higher in initially he

92 05) were significant predictors of treatment discontinuation, but sex and cardiac progression at base

93 disease progression or until other treatment discontinuation criteria were met.

94 y cycles, until disease progression or other discontinuation criteria were met.

95 cycles) until disease progression or another discontinuation criterion was met.

96 every 12 weeks thereafter until a treatment discontinuation criterion was met.

97 owed for 182 days post-discharge to identify discontinuation, defined as 60 continuous days without s

98 The number discontinuing and the time to discontinuation did not differ among regimens.

99 The number discontinuing and the time to discontinuation did not differ among study regimens (P =

100 ms were common with medication use, although discontinuation due to adverse effects was usually less

101 DR-LTBI regimens often resulted in treatment discontinuation due to adverse effects.

102 .76; 95% CI, 1.34-2.32; P < .001), and study discontinuation due to adverse events (RR, 1.79; 95% CI,

103 R, 1.76; 95% CI, 1.33-2.34; I, 0%) and study discontinuation due to adverse events (RR, 2.17; 95% CI,

104 herapies and estimated the risk of recurrent discontinuation due to adverse events or ineffectiveness

105 Discontinuation due to adverse events were similar in bo

106 Rates of discontinuation due to side effects were lower among tho

107 Discontinuation due to unsatisfactory treatment was 6.3

108 Serious adverse events and study drug discontinuations due to adverse events occurred in 4.8%

109 There were no serious adverse events or discontinuations due to adverse events.

110 Adverse events led to treatment discontinuation for 13 patients receiving ADS-5102 (20.6

111 rly and/or unnecessary tapering or treatment discontinuation for drug-related adverse events may not

112 ficantly higher reported rates of medication discontinuation for hyperlipidemia (60.7% vs 43.2%, P <

113 e increased toxicity, which led to treatment discontinuation for most patients during the induction p

114 The median follow-up after ruxolitinib discontinuation for the remaining 56 patients was 32 mon

115 Discontinuations for toxicity occurred in 7.8% and 23.1%

116 Rates for drug discontinuation, frequency of adverse events, disease pr

117 e novo liver transplant recipients allows CS discontinuation from day 1 posttransplant with good tole

118 ants were randomised to either the immediate discontinuation group (IDG) or the tapered group (TG).

119 Therefore, antihyperlipidemic discontinuation has been hypothesized to result in under

120 ity was observed in the year after clozapine discontinuation (hazard ratio: 2.65, 95% CI: 1.47-4.78).

121 0.78, 95% CI=0.69-0.88), index antipsychotic discontinuation (hazard ratio=0.60, 95% CI=0.55-0.65), a

122 Side effects lead to therapy discontinuation in 32%.

123 METHOD: In the Antipsychotic Discontinuation in Alzheimer's Disease trial, 180 patien

124 ervational study designed to evaluate 2G-TKI discontinuation in chronic myeloid leukemia (CML).

125 dverse events (any grade) prompted treatment discontinuation in four (11%) patients in the every-12-w

126 f the conjugated antibodies, cause treatment discontinuation in many patients.

127 Here we describe outcomes after ruxolitinib discontinuation in MF patients enrolled in a phase 1/2 s

128 on phase, respectively, and led to treatment discontinuation in one (4%) patient treated with 200 mg

129 f dose of ACEI and ARBs on outcomes and drug discontinuation in patients with HF with reduced ejectio

130 Reasons for treatment discontinuation in pharmacotherapy trials were infrequen

131 rgent adverse events, and these caused study discontinuation in six patients (5%) versus five patient

132 concerns about risks associated with aspirin discontinuation in the absence of major surgery or bleed

133 Adverse events led to treatment discontinuation in two (2%) patients in the placebo grou

134 chemic stroke (IS) due to statin and fibrate discontinuation in warfarin users, in which warfarin was

135 Reason for ECMO discontinuation included native lung recovery (54%), org

136 dverse events, and adverse events leading to discontinuation increased with worsening UACR status at

137 Cotrimoxazole (CTX) discontinuation increases malaria incidence in human imm

138 efits of statins accrue over time, treatment discontinuation is common.

139 he observed excess mortality after clozapine discontinuation is confounded by nonadherence and other

140 Therefore, even after discontinuation, many patients may continue to derive be

141 stence of IgE blocking antibody 1 year after discontinuation might be an early indicator of a protole

142 were associated with a lower risk for statin discontinuation (moderate intensity: relative risk [RR],

143 (months 12-15) and 3 months after study drug discontinuation (months 30-33).

144 biologic therapy were predictors of overall discontinuation (multivariable Cox proportional hazard m

145 ts were event-free survival (EFS), treatment discontinuation, no complete response (CR) or unconfirme

146 Furthermore, substantial treatment discontinuation occurred because of excessive toxicity,

147 Es), Grade 4 AEs or AEs leading to treatment discontinuation occurred.

148 No discontinuations occurred because of adverse events, ser

149 No treatment-related deaths or discontinuations occurred.

150 Adverse events caused the premature study discontinuation of 12 individuals (4.4%) in the safinami

151 ts was 32 months, with median survival after discontinuation of 14 months.

152 the last cell infusion and 7 weeks after the discontinuation of all immunosuppression to test immune

153 3% at a mean time of 6.4 +/- 3.3 weeks after discontinuation of anti-CMV therapy.

154 Prompt recognition and discontinuation of anti-PD-1 therapy is recommended.

155 Discontinuation of anti-TNF therapy or switching from co

156 tapered over a period of several weeks, but discontinuation of antidepressants may be associated wit

157 Discontinuation of ASA in the 62 patients (19.7%) who ha

158 se events (65%) and 2 deaths on study led to discontinuation of bendamustine and cessation of enrollm

159 e of the CV liabilities that resulted in the discontinuation of BMS-605339 (1) from clinical trials.

160 Discontinuation of CIH did not elicit significant improv

161 Discontinuation of CTX by HIV-infected adults receiving

162 apy or reduction, temporary interruption, or discontinuation of direct oral factor Xa inhibitor) and

163 Finally, after discontinuation of docetaxel therapy, median tumour grow

164 rred in two patients, resulting in the early discontinuation of eltrombopag.

165 Discontinuation of eOC was effective in 25 (89.3%) of 28

166 ected to be related to treatment that led to discontinuation of everolimus and exemestane (the most c

167 ate model identified factors associated with discontinuation of evolocumab.

168 In conclusion, discontinuation of first-line or subsequent 2G-TKI yield

169 Further research should investigate whether discontinuation of gemfibrozil in warfarin users results

170 After discontinuation of hormonal contraception, the risk of b

171 cient mice do not resolve inflammation after discontinuation of imiquimod challenge.

172 ecific chimerism, immune reconstitution, and discontinuation of immunoglobulin replacement therapy we

173 To examine successful discontinuation of inappropriate medication use and to i

174 Discontinuation of injectable disease-modifying therapy

175 Discontinuation of IRS in an area with historically high

176 During the 4-18 months following discontinuation of IRS, absolute TPR values increased by

177 In long-term users, discontinuation of low-dose aspirin in the absence of ma

178 Discontinuation of low-dose naltrexone resulted in flari

179 differences in adverse reactions leading to discontinuation of LTBI treatment.

180 elevations, and adverse reactions leading to discontinuation of LTBI treatment.

181 in English that addressed dose reduction or discontinuation of LTOT for chronic pain.

182 ent of hyperuricemia to prevent attacks, and discontinuation of medications for chronic gout in adult

183 y necessitated a switch to new drugs and the discontinuation of older ones, after which resistance of

184 Discontinuation of omalizumab was associated with an inc

185 -up and modify decision-making regarding the discontinuation of oral anticoagulant therapy.

186 patients to encounter families who object to discontinuation of organ support after death by neurolog

187 situations involving families who object to discontinuation of organ support after declaration of de

188 Treatment-related adverse events led to discontinuation of pembrolizumab and ipilimumab in 22 (1

189 ma can have durable complete remission after discontinuation of pembrolizumab, and the low incidence

190 report our experience treating HAE-FXII with discontinuation of potential trigger factors and drug th

191 At 1 week and 2 weeks after discontinuation of PPIs, biopsies showed significant inc

192 -term results have been reported after rapid discontinuation of prednisone (RDP) in kidney transplant

193 troenterological Association recommended the discontinuation of radiographic surveillance after 5 yea

194 arning theories predict extinction after the discontinuation of reinforcement through prediction erro

195 show little extinction and persist after the discontinuation of reinforcement.

196 nosa was initiated, the former necessitating discontinuation of rifampicin.

197 sociated with a higher risk of relapse after discontinuation of risperidone compared with continued r

198 As reported previously, discontinuation of risperidone was associated with a two

199 Due to discontinuation of routine vaccination more than 30 year

200 Discontinuation of screening should be considered when p

201 nts, and adverse events leading to permanent discontinuation of study drug or withdrawal from study w

202 No adverse events led to discontinuation of study drug, and no serious adverse ev

203 nd should be continued for 6-12 months after discontinuation of such immunosuppressive therapies to p

204 AE, laboratory abnormality, or AE leading to discontinuation of the drug was more likely with methotr

205 among the infected population, and after the discontinuation of the drug, by affecting the competitio

206 n OCT findings in the affected eyes included discontinuation of the ellipsoid zone and hyperreflectiv

207 Discontinuation of the first biologic therapy because of

208 Secondary outcomes included discontinuation of the index antipsychotic, use of an ad

209 3 and 4 adverse events and time to permanent discontinuation of the study regimen.

210 dual-placebo group, but the overall rate of discontinuation of the trial regimen was similar in the

211 rt for the immunization programs, and sudden discontinuation of their employment would potentially di

212 inical remission, there is often interest in discontinuation of therapy due to safety or economic con

213 4-22) terlipressin-treated patients required discontinuation of therapy due to serious adverse events

214 Discontinuation of therapy due to side effects was signi

215 Adverse events led to discontinuation of therapy in five (10%) patients (atria

216 However, discontinuation of therapy rapidly increases virus burde

217 rologic response (SVR) at 24 weeks following discontinuation of therapy were identified using a logis

218 al of hepatorenal syndrome had recurrence on discontinuation of therapy.

219 atients at a median of 51 (0-160) days after discontinuation of therapy.

220 site with no recrudescence up to 122 d after discontinuation of therapy.

221 lapril had no further HAE-FXII attacks after discontinuation of those drugs.

222 Importance: The optimal timing of discontinuation of ticagrelor before cardiac surgery is

223 ficacies, cognitive and depressive symptoms, discontinuation of treatment because of any cause, and i

224 Discontinuation of treatment in 59 (27%) participants on

225 e patients with prior myocardial infarction, discontinuation of treatment with ticagrelor was driven

226 of adverse events due to dyspnea that led to discontinuation of treatment with ticagrelor were mild o

227 x percent of bleeding events that led to the discontinuation of treatment with ticagrelor were nonmaj

228 ipients, and enhanced survival of mice after discontinuation of treatment, in comparison with NIL alo

229 The relapse rate was 44% 18 months after discontinuation of treatment.

230 rove symptoms for at least 2 years following discontinuation of treatment.

231 rosis factor inhibitors, but did not lead to discontinuation of treatment.

232 nd are responsible for CML relapse following discontinuation of treatment.

233 ality of life and, thus, may precipitate the discontinuation of treatments and underscore the need fo

234 Discontinuation of tyrosine kinase inhibitor (TKI) thera

235 Successful discontinuation of use of at least 1 inappropriate drug

236 These findings indicate that discontinuation of warfarin treatment after PVI is not s

237 s were mild or moderate in severity, with no discontinuations of the trial regimen due to adverse eve

238 acebo died on treatment or within 30 days of discontinuation, of which eight (3%) and five (2%) death

239 METHODS AND We defined deintensification as discontinuation or dosage decrease of at least 1 glycemi

240 st common adverse event associated with drug discontinuation or dose changes (215 [7%] of 3263 patien

241 lare, six of whom had reactivation, required discontinuation or dose reduction of cancer treatment.

242 chiatric rehospitalization, suicide attempt, discontinuation or switch to other medication, or death)

243 Rates of discontinuation or treatment switching did not differ be

244 re were no deaths, adverse events leading to discontinuation, or serious adverse events.

245 event, followed by statin down-titration or discontinuation, or switching between >/=3 types of stat

246 No serious adverse events, discontinuations, or deaths were associated with this re

247 Rates of discontinuation owing to side effects were 35% for INH,

248 ction = .004) and decreased after medication discontinuation (P-trend < .001).

249 s and was managed with dose de-escalation or discontinuation per standard of care.

250 heir first prescription until MI, medication discontinuation, plan disenrollment, or December 31, 201

251 ion on antipsychotic reduction that prevents discontinuation; predictors of poor response could not b

252 dian follow-up of approximately 2 years from discontinuation provides hope for a cure for some patien

253 reported dose reduction, but rates of opioid discontinuation ranged widely across interventions and t

254 The discontinuation rate in the intervention group was 21.8%

255 Discontinuation rates (DRs) per 100 patient-years were e

256 The discontinuation rates are annualized for patients who re

257 eports of community-based use have estimated discontinuation rates as high as 40% in the first year o

258 We also found high treatment discontinuation rates due to adverse effects in persons

259 Discontinuation rates were also not significantly differ

260 Discontinuation rates were significantly higher in the v

261 Examining the patterns of statin discontinuation, reinitiation, and persistence after rei

262 Numbers of discontinuations related to adverse events (11 [1%] of 7

263 fic QOL, was associated with early treatment discontinuation (relative risk, 1.79; 95% CI, 1.53 to 2.

264 Discontinuation resulting from AEs occurred in seven (13

265 larly auditory hallucinations, antipsychotic discontinuation should be approached cautiously because

266 vs 121 [49%]) or adverse events that led to discontinuation (ten [4%] vs 17 [7%]).

267 sidized race or ethnicity groups had greater discontinuation than subsidized groups (white patients:

268 ays immediately following antihyperlipidemic discontinuation, the exposure of interest.

269 llow-up of more than 6 years after treatment discontinuation, the STIM1 study demonstrates that IM ca

270 s 2015 rates of testing, ART initiation, ART discontinuation, treatment failure, and levels of condom

271 ections) in intensity and rarely resulted in discontinuation (two [<1%] of 230 patients); injection-s

272 , every 9 weeks thereafter, at the treatment discontinuation visit, and at the 30-day safety assessme

273 n time from specimen collection to acyclovir discontinuation was 17.1 h shorter in the postimplementa

274 Median time to prednisone discontinuation was 35.8 months with prednisone alone co

275 e median molecular follow-up after treatment discontinuation was 77 months (range, 9 to 95 months).

276 ension (p = 1.0) that resulted in study drug discontinuation was comparable between the two groups.

277 Discontinuation was defined by not having a statin avail

278 previously tolerated, dosage adjustments or discontinuation was frequent and support the need for ho

279 discontinued treatment; the main reason for discontinuation was gastrointestinal adverse events such

280 In univariable analyses, discontinuation was lowest among children (relative risk

281 In multivariable analyses, discontinuation was lowest among contacts of patients wi

282 By contrast, cannabis discontinuation was not associated with relapse (dDC-NC=

283 Permanent discontinuation was reported in 19 patients (31.7%) rece

284 Dofetilide dose adjustment or discontinuation was required in 30 of 102 patients (29.4

285 Dose adjustment or discontinuation was required in 44 patients (31.9%).

286 Treatment discontinuation was significantly associated with change

287 rmatologic reactions, and cause of treatment discontinuation were annotated.

288 of therapy or <100 x 10(9)/L at the time of discontinuation were associated with shorter survival af

289 However, rates of adverse events and discontinuation were generally higher in patients treate

290 ates of serious adverse events and treatment discontinuation were low (<10% in the general population

291 Common reasons for treatment discontinuation were progressive disease in 34 (24%) pat

292 AEs leading to discontinuation were reported in 6.8% of those receiving

293 rse event rates within 30 days of study drug discontinuation were similar between groups (serious adv

294 and rates of bleeding leading to study drug discontinuation were similar in the edoxaban and warfari

295 No discontinuations were attributed to treatment-related ad

296 Most discontinuations were due to adverse events-mostly gastr

297 function allowing renal replacement therapy discontinuation when baseline estimated glomerular filtr

298 viral load >/=50 copies per mL or premature discontinuations, with last viral load >/=50 copies per

299 icipant characteristics, and early treatment discontinuation within the Mammary Prevention.3 (MAP.3)

300 at 12 and 24 months, respectively, after NA discontinuation without being affected by the duration o